<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJEMD</journal-id><journal-title-group><journal-title>Open Journal of Endocrine and Metabolic Diseases</journal-title></journal-title-group><issn pub-type="epub">2165-7424</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojemd.2021.111002</article-id><article-id pub-id-type="publisher-id">OJEMD-106705</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  The Association of Visceral Adiposity Index with Insulin Resistance in Adults with Prediabetes
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Md.</surname><given-names>Shahed-Morshed</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tahniyah</surname><given-names>Haq</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Md.</surname><given-names>Fariduddin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sultana</surname><given-names>Parveen</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tohfa-E-Ayub</surname><given-names>&amp;nbsp;</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Naureen</surname><given-names>Mahbub</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>M.</surname><given-names>A. Hasanat</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Emergency, Kurmitola General Hospital, Dhaka, Bangladesh</addr-line></aff><aff id="aff4"><addr-line>Intensive Care Unit, Bangladesh Institute of Research &amp;amp; Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
(BIRDEM), Shahbag, Dhaka, Bangladesh</addr-line></aff><aff id="aff2"><addr-line>Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh</addr-line></aff><aff id="aff3"><addr-line>Department of Biochemistry, Ibrahim Medical College (IMC), 1/A Ibrahim Sarani, Segunbagicha, Dhaka, Bangladesh</addr-line></aff><pub-date pub-type="epub"><day>18</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>12</fpage><lpage>23</lpage><history><date date-type="received"><day>8,</day>	<month>October</month>	<year>2020</year></date><date date-type="rev-recd"><day>19,</day>	<month>January</month>	<year>2021</year>	</date><date date-type="accepted"><day>22,</day>	<month>January</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Visceral adiposity mediates insulin resistance, but their association among adults with prediabetes is scarce in the literature. This study is aimed to determine the association of visceral adiposity index (VAI) with insulin resistance in adults with prediabetes. This cross-sectional study was done among 117 adults with newly detected prediabetes [m/f; 23/94; mean &#177; SD: Age 36.30 &#177; 9.99 years, BMI 28.89 &#177; 4.35 kg/m<sup>2</sup>] based on American Diabetes Association 2018 criteria and 141 matched healthy controls [m/f: 28/113; mean &#177; SD: 35.30 &#177; 6.88 years, BMI 25.03 &#177; 4.58]. Waist circumference, body mass index, fasting triglyceride, HDL cholesterol, fasting blood glucose and insulin were measured in each group to calculate VAI and homeostatic model assessment of insulin resistance (HOMA-IR). People with prediabetes had significantly higher median value of VAI {3.08 (2.26) vs. 1.86 (2.31); p &lt; 0.001} with higher frequency of high VAI (&gt;1) (98.3% vs. 85.8%; p &lt; 0.001) than the control population. HOMA-IR level was significantly higher in prediabetes with high VAI (cut-off of 2.64) than control with normal VAI [2.78 (2.22, 4.15) vs. 2.20 (1.53, 3.36); p = 0.002]. VAI was positively correlated with HOMA-IR in females with prediabetes (r = 0.299, p = 0.003). VAI had predictive association with prediabetes [OR (95% CI: 9.504 (2.173, 41.576); p = 0.03] and high insulin resistance (HOMA-IR ≥ 2.6) in females with prediabetes [OR (95% CI) = 3.50 (1.476, 8.297); p = 0.004] only. It could satisfactorily discriminate prediabetes in both sexes (male: AUC = 0.767, p = 0.001; female: AUC = 0.641, p &lt; 0.001) and high insulin resistance in females with prediabetes (AUC = 0.641; p = 0.019) only. So, VAI was associated with prediabetes and insulin resistance only in females with prediabetes. 
  
 
</p></abstract><kwd-group><kwd>Visceral Adiposity Index</kwd><kwd> Insulin Resistance</kwd><kwd> Prediabetes</kwd><kwd> Homeostatic Model Assessment of Insulin Resistance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Bangladesh is now dealing with a huge burden of diabetes and prediabetes [<xref ref-type="bibr" rid="scirp.106705-ref1">1</xref>]. Prediabetes is the preceding stage of development of DM. It is associated with insulin resistance, metabolic syndrome and cardiovascular diseases [<xref ref-type="bibr" rid="scirp.106705-ref2">2</xref>]. These are mediated via several products including cytokines and free fatty acids secreted in the portal circulation from the visceral fat reaching directly to the liver [<xref ref-type="bibr" rid="scirp.106705-ref3">3</xref>]. Thus, measurement of visceral adiposity may give an early clue of insulin resistance and dysglycemia. High visceral adiposity is now considered as a cardiometabolic risk factor [<xref ref-type="bibr" rid="scirp.106705-ref4">4</xref>]. The gold standard imaging based assessment of visceral adiposity is expensive and impractical in daily practice. Visceral adiposity index (VAI) is a simple clinico-biochemical and gender-specific tool that represents adipose tissue dysfunction and ultimate insulin resistance. It is better than body mass index (BMI) and waist circumference (WC) alone to predict cardiovascular events. So, VAI can be used as an early indicator of cardiometabolic risk especially in patients before developing overt metabolic syndrome [<xref ref-type="bibr" rid="scirp.106705-ref5">5</xref>]. However, visceral adiposity is dependent on ethnicity [<xref ref-type="bibr" rid="scirp.106705-ref6">6</xref>]. So, VAI cut-off should be population specific. Previous study found an association of VAI with insulin resistance in adults with DM [<xref ref-type="bibr" rid="scirp.106705-ref7">7</xref>]. However, the association of VAI with insulin resistance in prediabetes has not been studied among Bangladeshi adults. Furthermore, data regarding this association among adults with prediabetes is scarce in the literature. Therefore, we decided to look at the association of VAI and insulin resistance in adults with prediabetes, and see whether VAI could predict insulin resistance and prediabetes.</p></sec><sec id="s2"><title>2. Methodology</title><p>This cross-sectional study was done in the Department of Endocrinology, BSMMU and BIRDEM general hospital among 117 adults with newly detected prediabetes and 141 matched healthy control population over a period of two years (July 2017 to June 2019). People with overt cardiac, renal, hepatic, inflammatory and autoimmune diseases; women with pregnancy or lactation or taking any form of estrogen; people taking steroid or antilipid drugs were excluded from the study. Informed consent was taken from each participant. The study protocol was approved by the institutional review board of BSMMU and Bangladesh Diabetes Association (BADAS).</p><sec id="s2_1"><title>2.1. Study Protocol</title><p>The participants’ age, sex and family history were documented and height, weight &amp; WC were measured as per standard procedure [<xref ref-type="bibr" rid="scirp.106705-ref8">8</xref>]. BMI was calculated from weight and height {1) BMI = weight in kg &#247; (height in meter)<sup>2</sup>}. Venous blood was collected after 8 - 12 hours of fasting for measurement of fasting blood glucose, serum fasting insulin, serum triglyceride (TG) and serum high density lipoprotein cholesterol (HDL-C). Blood glucose was measured by glucose oxidase method. Rest of the blood was allowed to clot. After centrifugation for 10 minutes at a spun of 3000 rpm, separated plasma was stored at −20˚C until assay after proper labeling. Fasting insulin was measured by chemiluminescent microparticle immunoassay with ARCHITECT Insulin assay Abbott, USA with a coefficient of variability ≤ 7%. Assay of fasting TG and HDL-C were done by glycerol phosphate dehydrogenase-peroxidase and precipitating method respectively using total cholesterol enzymatic reagent [<xref ref-type="bibr" rid="scirp.106705-ref9">9</xref>].</p></sec><sec id="s2_2"><title>2.2. Operational Definitions</title><sec id="s2_2_1"><title>2.2.1. Prediabetes</title><p>It was diagnosed according to American Diabetes Association 2018 criteria {any one from below: fasting blood glucose, FBG = 5.6 - 6.9 mmol/L (IFG), 2 hours after 75 gm OGTT = 7.8 - 11 mmol/L (IGT) or HbA<sub>1C</sub> = 5.7% - 6.4%} and control was defined only by fasting blood glucose criteria [<xref ref-type="bibr" rid="scirp.106705-ref2">2</xref>].</p></sec><sec id="s2_2_2"><title>2.2.2. Obesity and Central Obesity</title><p>The cut-off value to define obesity and central obesity were of BMI of 25 Kg/m<sup>2</sup> and WC of 90 cm for males &amp; 80 cm for females respectively [<xref ref-type="bibr" rid="scirp.106705-ref10">10</xref>].</p></sec><sec id="s2_2_3"><title>2.2.3. Hypertriglyceridemia and Low HDL-C</title><p>They were defined by their metabolic syndrome criteria (TG ≥150 mg/dl; HDL-C &lt; 40 mg/dl for males and &lt;50 for females) [<xref ref-type="bibr" rid="scirp.106705-ref11">11</xref>].</p></sec><sec id="s2_2_4"><title>2.2.4. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title><p>HOMA-IR is a validated tool for measuring insulin resistance in clinical practice that was calculated from the following formula.</p><p>2) HOMA-IR = {fasting insulin (&#181;IU/ml) &#215; FBG (mmol/L)} &#247; 22.5 [<xref ref-type="bibr" rid="scirp.106705-ref12">12</xref>].</p><p>The cut-off value to define high insulin resistance and hyperinsulinemia were 2.6 and 12 &#181;IU/ml respectively for Bangladeshi population [<xref ref-type="bibr" rid="scirp.106705-ref13">13</xref>].</p></sec><sec id="s2_2_5"><title>2.2.5. VAI</title><p>It was calculated from clinical (BMI, WC) and biochemical (TG, HDL-C) parameters with different formula for each sex.</p><p>3) Male: VAI = {WC in cm &#247; 39.68 + (1.88 &#215; BMI in kg/m<sup>2</sup>)} &#215; (TG in mmol/L &#247; 1.03) &#215; (1.31 &#247; HDL-C in mmol/L)</p><p>4) Female: VAI = {WC in cm &#247; 36.58 + (1.89 &#215; BMI in kg/m<sup>2</sup>)} &#215; (TG in mmol/L &#247; 0.81) &#215; (1.52 &#247; HDL-C in mmol/L)</p><p>VAI of 1 is considered as normal visceral adiposity. The cut-off value of VAI &gt; 1 was considered as high in this study [<xref ref-type="bibr" rid="scirp.106705-ref4">4</xref>]. Another cut-off of VAI (2.64) was derived from receiver operating characteristics (ROC) curve to discrimiate high insulin resistance from normal in people with prediabetes.</p></sec></sec><sec id="s2_3"><title>2.3. Statistical Analysis</title><p>All data were entered, edited and analyzed by computer-based SPSS program (version 22.0). The quantitative values were expressed in mean &#177; standard deviation (SD) for normally distributed values or median (interquartile range, IQR) for skewed values (TG, fasting insulin, HOMA-IR and VAI). The qualitative values were expressed in frequency (percentages, %). To compare the mean value of groups (prediabetes vs. control, insulin resistance high vs. normal and high vs. normal VAI), independent-samples T test and for median value Mann Whitney U test or Kruskal-wallis test were done as appropriate. To test the association between categories (study groups, insulin resistance status and VAI status) Pearson’s chi-square test or Fisher’s exact test was done as applicable. ROC curves were analyzed to see whether VAI could discriminate presence of high insulin resistance and prediabetes. Logistic regression analyses were done to see whether high VAI could predict prediabetes and high insulin resistance. P &lt; 0.05 was taken as statistically significant.</p></sec></sec><sec id="s3"><title>3. Results</title><p>A total of 258 adults (117 with prediabetes and 141 healthy matched control) were included in this study. The study population was relatively young (mean age &lt; 40 years) with a female predominance (~80% female). The adults with prediabetes had a significantly higher family history of DM than the control population. The frequency of obesity, central obesity, low HDL-C, hypertriglyceridemia and high VAI (&gt;1) were significantly higher in people with prediabetes than the control population. Similarly, the mean or median value of BMI, WC, FBG, TG and VAI were significantly higher in the participants with prediabetes. However, the HDL-C was not found significantly lower in female with prediabetes. HOMA-IR level was significantly higher in prediabetes than control due to significant differences in fasting blood glucose (<xref ref-type="table" rid="table1">Table 1</xref>(a) &amp; <xref ref-type="table" rid="table1">Table 1</xref>(b)).</p><p>VAI level was not associated with insulin resistance status (cut-off of 2.6) in the study population [normal vs. high insulin resistance {median (IQR)}: total population 2.23 (1.49, 3.67) vs. 2.79 (1.65, 4.27), p = 0.053; control 1.70 (1.22, 3.37) vs. 1.96 (1.47, 3.89), p = 0.249 and prediabetes: 2.49 (2.05, 4.11) vs. 3.48 (2.20, 5.01), p = 0.196)]. Similarly VAI status (cut-off of &gt;1) was not associated with insulin resistance status in the study population [normal vs. high insulin resistance {frequency (%)}: total population 132 (91.0%) vs. 104 (92.0%), p = 0.826; control 73 (85.9%) vs. 48 (85.7%), p = 1.00; prediabetes 59 (98.3%) vs. 56 (98.2%); p = 1.00] (not shown).</p><p>Total study population was divided into four groups by considering glycemic status (prediabetes and control) and VAI status (high and normal by cut-off of 1</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> (a) Characteristics [frequency (%)] of the study population (N = 258); (b) Clinical and biochemical variables [mean &#177; SD or median (IQR)] of the study population (N = 258)</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Variables</th><th align="center" valign="middle" >Control (n = 141)</th><th align="center" valign="middle" >Prediabetes (n = 117)</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Frequency (%)</td></tr><tr><td align="center" valign="middle" >Sex (female)</td><td align="center" valign="middle" >113 (80.1)</td><td align="center" valign="middle" >94 (80.3)</td><td align="center" valign="middle" >1.00</td></tr><tr><td align="center" valign="middle" >Family history of diabetes mellitus</td><td align="center" valign="middle" >48 (34.0)</td><td align="center" valign="middle" >71 (60.7)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Obese (BMI ≥ 25 kg/m<sup>2</sup>)</td><td align="center" valign="middle" >60 (42.6)</td><td align="center" valign="middle" >94 (80.3)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Centrally obese (Male ≥ 90 cm, female ≥ 80 cm)</td><td align="center" valign="middle" >102 (72.3)</td><td align="center" valign="middle" >108 (92.3)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Low HDL-C (Male &lt; 40 cm, female &lt; 50 mg/dl)</td><td align="center" valign="middle" >84 (59.6)</td><td align="center" valign="middle" >87 (74.4)</td><td align="center" valign="middle" >0.017</td></tr><tr><td align="center" valign="middle" >Hypertriglyceridemia (Serum TG ≥ 150 mg/dl)</td><td align="center" valign="middle" >30 (21.3)</td><td align="center" valign="middle" >60 (51.3)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Hyperinsulinemia (≥12 mIU/ml)</td><td align="center" valign="middle" >72 (51.1)</td><td align="center" valign="middle" >47 (40.2)</td><td align="center" valign="middle" >0.103</td></tr><tr><td align="center" valign="middle" >High insulin resistance (HOMA-IR ≥ 2.6)</td><td align="center" valign="middle" >56 (39.7)</td><td align="center" valign="middle" >57 (48.7)</td><td align="center" valign="middle" >0.166</td></tr><tr><td align="center" valign="middle" >High VAI (&gt;1)</td><td align="center" valign="middle" >121 (85.8)</td><td align="center" valign="middle" >115 (98.3)</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"   rowspan="2"  >Variables</th><th align="center" valign="middle" >Control (n = 141)</th><th align="center" valign="middle" >Prediabetes (n = 117)</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >mean &#177; SD or median (IQR)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Age (years)</td><td align="center" valign="middle" >35.30 &#177; 6.88</td><td align="center" valign="middle" >36.30 &#177; 9.99</td><td align="center" valign="middle" >0.359</td></tr><tr><td align="center" valign="middle"  colspan="2"  >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >25.03 &#177; 4.58</td><td align="center" valign="middle" >28.89 &#177; 4.35</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >WC (cm)</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >83.61 &#177; 12.38</td><td align="center" valign="middle" >94.77 &#177; 14.50</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >88.40 &#177; 10.64</td><td align="center" valign="middle" >98.33 &#177; 9.74</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >FBG (mmol/L)</td><td align="center" valign="middle" >4.34 &#177; 0.89</td><td align="center" valign="middle" >5.79 &#177; 0.62</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Serum HDL-C (mg/dl)</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >50.36 &#177; 13.81</td><td align="center" valign="middle" >37.09 &#177; 7.43</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >42.35 &#177; 16.87</td><td align="center" valign="middle" >42.94 &#177; 9.47</td><td align="center" valign="middle" >0.753</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Serum TG (mg/dl)</td><td align="center" valign="middle" >103.90 (76.55, 143.25)</td><td align="center" valign="middle" >151.0 (114.50, 203.5.0)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Serum fasting insulin (&#181;IU/ml)</td><td align="center" valign="middle" >12.0 (6.91, 17.59)</td><td align="center" valign="middle" >10.80 (7.25, 14.70)</td><td align="center" valign="middle" >0.172</td></tr><tr><td align="center" valign="middle"  colspan="2"  >HOMA-IR</td><td align="center" valign="middle" >2.24 (1.27, 3.34)</td><td align="center" valign="middle" >2.56 (1.93, 3.69)</td><td align="center" valign="middle" >0.012</td></tr><tr><td align="center" valign="middle"  colspan="2"  >VAI</td><td align="center" valign="middle" >1.86 (1.26, 3.57)</td><td align="center" valign="middle" >3.08 (2.07, 4.33)</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap></table-wrap-group><p>&amp; 2.64). VAI &gt; 1 indicates any abnormality in BMI, WC, TG or HDL-C. Similarly, the cut-off of 2.64 was derived from a ROC curve to discriminate high insulin resistance with a sensitivity and specificity of 50.4% and 62.8% respectively in the study population. There was no statistically significant association found between VAI and insulin resistance in prediabetes and control, except the median value of HOMA-IR when VAI cut off of 2.64 were used (<xref ref-type="table" rid="table2">Table 2</xref>(a) and <xref ref-type="table" rid="table2">Table 2</xref>(b)). Post hoc analysis (pairwise comparison) showed that HOMA-IR was significantly higher in prediabetes group with high VAI (≥2.64) than normal VAI with both control (p = 0.002) and prediabetes (p = 0.032).</p><p>VAI was significantly and positively correlated with HOMA-IR in people with prediabetes (r = 0.223, p = 0.015) but not in control (r = 0.132, p = 0.119) population. Furthermore, the significant correlation was found only in female participants (r = 0.299, p = 0.003) with prediabetes (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>Linear regression analysis revealed that VAI level was not significantly associated with HOMA-IR level in the study population [Total: β = 0.09, p = 0.150; control: β = 0.057, p = 0.499 and prediabetes: β = 0.085; p = 0.361). VAI &gt; 1 had a higher odds of developing prediabetes [OR (95% CI) = 9.504 (2.173, 41.576); p</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> (a) Association of HOMA-IR and VAI (cut-off of &gt;1) in the study population (N = 258); (b) Association of HOMA-IR and VAI (cut-off of 2.64) in the study population (N = 258)</title></caption><table-wrap id="2_1"><caption><title> (b)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Study groups</th><th align="center" valign="middle"  rowspan="2"  >VAI status</th><th align="center" valign="middle" >HOMA-IR</th><th align="center" valign="middle"  rowspan="2"  >p</th><th align="center" valign="middle" >High IR</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >median (IQR)</td><td align="center" valign="middle" >frequency (%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Control (n = 141)</td><td align="center" valign="middle" >Normal VAI (n = 20)</td><td align="center" valign="middle" >1.68 (0.78, 2.91)</td><td align="center" valign="middle"  rowspan="4"  >0.069</td><td align="center" valign="middle" >8 (7.1)</td><td align="center" valign="middle"  rowspan="4"  >0.533</td></tr><tr><td align="center" valign="middle" >High VAI (n = 121)</td><td align="center" valign="middle" >2.25 (1.38, 3.36)</td><td align="center" valign="middle" >48 (42.5)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Prediabetes (n = 117)</td><td align="center" valign="middle" >Normal VAI (n = 2 )</td><td align="center" valign="middle" >6.52 (1.25)</td><td align="center" valign="middle" >1 (0.9)</td></tr><tr><td align="center" valign="middle" >High VAI (n = 115 )</td><td align="center" valign="middle" >2.56 (1.94, 3.63)</td><td align="center" valign="middle" >56 (49.6)</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><caption><title></title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Study groups</th><th align="center" valign="middle"  rowspan="2"  >VAI status</th><th align="center" valign="middle" >HOMA-IR median</th><th align="center" valign="middle"  rowspan="2"  >p</th><th align="center" valign="middle" >High IR</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >(IQR)</td><td align="center" valign="middle" >frequency (%)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Control (n = 141)</td><td align="center" valign="middle" >Normal VAI (n = 94)</td><td align="center" valign="middle" >2.22 (1.53, 3.36)</td><td align="center" valign="middle"  rowspan="4"  >0.002</td><td align="center" valign="middle" >36 (38.3)</td><td align="center" valign="middle"  rowspan="4"  >0.097</td></tr><tr><td align="center" valign="middle" >High VAI (n = 47)</td><td align="center" valign="middle" >2.40 (1.51, 3.12)</td><td align="center" valign="middle" >20 (42.6)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Prediabetes (n = 117)</td><td align="center" valign="middle" >Normal VAI (n = 52)</td><td align="center" valign="middle" >2.17 (1.57, 3.37)</td><td align="center" valign="middle" >20 (38.5)</td></tr><tr><td align="center" valign="middle" >High VAI (n = 65)</td><td align="center" valign="middle" >2.78 (2.22, 4.15)</td><td align="center" valign="middle" >37 (56.9)</td></tr></tbody></table></table-wrap></table-wrap-group><p>Kruskal-Wallis test and Pearson’s chi-square test were done respectively; IQR (interquartile range), HOMA-IR (homeostatic model assessment of insulin resistance), VAI (visceral adiposity index).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation of HOMA-IR with VAI in the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Study population</th><th align="center" valign="middle" >r</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Total</td><td align="center" valign="middle" >0.186</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Control (n = 141)</td><td align="center" valign="middle" >0.132</td><td align="center" valign="middle" >0.119</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Prediabetes (n = 117)</td><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >0.223</td><td align="center" valign="middle" >0.015</td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >−0.183</td><td align="center" valign="middle" >0.393</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >0.299</td><td align="center" valign="middle" >0.003</td></tr></tbody></table></table-wrap><p>Spearman’s rho correlation test was done, r = correlation coefficient; HOMA-IR (homeostatic model assessment of insulin resistance), VAI (visceral adiposity index).</p><p>= 0.003] (not shown). Those with a VAI of ≥2.64 had predictive association with high insulin resistance (≥2.6) in the study population [OR (95% CI) = 1.666 (1.012, 2.742); p = 0.045] and also in the prediabetes group [OR (95% CI) = 2.114 (1.005, 4.448); p = 0.048]. The association was only significant in the females with prediabetes [OR (95% CI) = 3.50 (1.476, 8.297); p = 0.004] (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>ROC curve analysis showed that VAI was an acceptable discriminator of prediabetes from control [area under the curve, AUC (95% confidence interval, CI) = 0.677 (0.612, 0.742); p &lt; 0.001) especially in males [AUC (95% CI) = 0.767 (0.637, 0.897); p = 0.001] than females [AUC (95% CI) = 0.654 (0.580, 0.729); p &lt; 0.001). With a VAI cut off of 1, the sensitivity and specificity were 98.3% and 14.2% respectively to discriminate prediabetes from control in the study population (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)). On the other hand, VAI was a less acceptable discriminator</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Logistic regression analysis for high VAI (cut-off of 2.64) in predicting high insulin resistance in the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Study groups</th><th align="center" valign="middle" >OR (95% CI)</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >1.666 (1.012, 2.742)</td><td align="center" valign="middle" >0.045</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >1.193 (0.585, 2.433)</td><td align="center" valign="middle" >0.627</td></tr><tr><td align="center" valign="middle" >Prediabetes (n = 117)</td><td align="center" valign="middle" >2.114 (1.005, 4.448)</td><td align="center" valign="middle" >0.048</td></tr><tr><td align="center" valign="middle" >Male (n = 23)</td><td align="center" valign="middle" >0.214 (0.032, 1.425)</td><td align="center" valign="middle" >0.111</td></tr><tr><td align="center" valign="middle" >Female (n = 94)</td><td align="center" valign="middle" >3.50 (1.476, 8.297)</td><td align="center" valign="middle" >0.004</td></tr></tbody></table></table-wrap><p>OR = Odds ratio; CI = confidence interval, VAI (visceral adiposity index).</p><p>of high insulin resistance in the study population [AUC (95% CI) = 0.570 (0.050, 0.641); p = 0.05] and not at all in people with prediabetes [AUC (95% CI) = 0.569 (0.464, 0.674); p = 0.196). However it was better in case of females [AUC (95% CI) = 0.641 (0.527, 0.755); p = 0.019] than males (AUC (95% CI) = 0.214 (0.005, 0.423); p = 0.023] in adults with prediabetes as a discriminator of high insulin resistance (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)).</p></sec><sec id="s4"><title>4. Discussion</title><p>This study is aimed to determine the level and status of VAI and its association with insulin resistance in adults with prediabetes. We found that VAI level and high VAI status were significantly higher in adults with prediabetes. Although high VAI status (cut off of &gt;1) was not associated with insulin resistance in the study population, HOMA-IR level was significantly higher in people with prediabetes with high VAI (cut off of 2.64) than control and prediabetes with low VAI. VAI was positively correlated with HOMA-IR in females with prediabetes. It had predictive association with prediabetes and high insulin resistance in females with prediabetes. It was also an acceptable discriminator of prediabetes in both sexes and insulin resistance only in females with prediabetes.</p><p>We found higher level of VAI and high VAI status in adults with prediabetes that were due to significantly higher BMI, WC, TG and lower HDL-C than the control population. So higher visceral obesity indicates poor glycemic status. Several studies also found similar findings [<xref ref-type="bibr" rid="scirp.106705-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref17">17</xref>]. High VAI was associated with future development of DM in prospective studies [<xref ref-type="bibr" rid="scirp.106705-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref19">19</xref>].</p><p>We found significantly higher HOMA-IR level in adults with prediabetes than control despite an insignificant difference in fasting insulin level. Similar finding was also described by a study [<xref ref-type="bibr" rid="scirp.106705-ref14">14</xref>]. The significant association was due to the significant differences in fasting blood glucose level. However, the frequency of high insulin status and high insulin resistance status were not statistically different between the study groups. The people having prediabetes with high VAI had higher HOMA-IR than people with or without prediabetes with normal VAI. So, VAI mediates higher insulin resistance at a higher glycemic status. Lipid profile might further contribute in insulin resistance [<xref ref-type="bibr" rid="scirp.106705-ref20">20</xref>].</p><p>This study found a positive correlation of HOMA-IR with VAI in females with prediabetes. VAI was negatively correlated with insulin sensitivity measured by euglycemic hyperinsulinemic clamp method in IFG but not IGT reported in one study [<xref ref-type="bibr" rid="scirp.106705-ref21">21</xref>]. Another study did not find significant correlation between HOMA-IR and VAI in prediabetes [<xref ref-type="bibr" rid="scirp.106705-ref14">14</xref>].</p><p>This study showed that High VAI was associated with increase risk of development of prediabetes and high insulin resistance in females with prediabetes. Several studies also found association of VAI with prediabetes with various odds ratios either using a cut-off to define high VAI or comparing the extreme groups made by various percentile values [<xref ref-type="bibr" rid="scirp.106705-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref23">23</xref>]. We also found an association of insulin resistance in females with prediabetes having high VAI. One study found the association of VAI with insulin resistance among subjects free of DM [<xref ref-type="bibr" rid="scirp.106705-ref19">19</xref>].</p><p>Our study found that VAI might be a useful discriminator of prediabetes from healthy population. Several studies also found a similar AUC value but different cut-offs for VAI to define high VAI status [<xref ref-type="bibr" rid="scirp.106705-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.106705-ref24">24</xref>]. Another study also found VAI as a discriminating index of prediabetes/diabetes (AUC = 0.69) but less good than lipid accumulation product and product of TG &amp; glucose [<xref ref-type="bibr" rid="scirp.106705-ref25">25</xref>]. Another study failed to show VAI as a discriminator of prediabetes [<xref ref-type="bibr" rid="scirp.106705-ref16">16</xref>]. We also found, VAI could acceptably discriminate insulin resistance in females with prediabetes. As per our best knowledge, this is the first report to mention the usefulness of VAI as a discriminator of insulin resistance in people with prediabetes.</p><p>The main limitation of the study was small sample size. Besides, the selection of control by only FBG criteria might include participants with IGT or raised HbA<sub>1C</sub> in the control population in this study.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In conclusion, this study found a positive association of VAI with prediabetes. The association of VAI with insulin resistance was only found in females with prediabetes. VAI could discriminate prediabetes from healthy control and insulin resistance only in females with prediabetes.</p></sec><sec id="s6"><title>Ethics</title><p>The institutional review board of BSMMU and Bangladesh Diabetes Association (BADAS) approved the study protocol.</p></sec><sec id="s7"><title>Submission Declaration</title><p>This article is not under consideration for publication elsewhere. If accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. All authors and responsible authorities where the work was carried out have approved its publication.</p>Data Availability Statement<p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p>Conflicts of Interest<p>The authors declare that they have no competing interests.</p></sec><sec id="s8"><title>Cite this paper</title><p>Shahed-Morshed, Md., Haq, T., Fariduddin, Md., Parveen, S., Tohfa-E-Ayub, Mahbub, N. and Hasanat, M.A. (2021) The Association of Visceral Adiposity Index with Insulin Resistance in Adults with Prediabetes. Open Journal of Endocrine and Metabolic Diseases, 11, 12-23. https://doi.org/10.4236/ojemd.2021.111002</p></sec></body><back><ref-list><title>References</title><ref id="scirp.106705-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">International Diabetes Federation (2019) IDF Diabetes Atlas. 9th Edition, Brussels. https://www.diabetesatlas.org</mixed-citation></ref><ref id="scirp.106705-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">American Diabetes Association (2018) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care, 41, S13-S27. https://doi.org/10.2337/dc18-S002</mixed-citation></ref><ref id="scirp.106705-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hardy, O.T., Czech, M.P. and Corvera, S. (2012) What Causes the Insulin Resistance Underlying Obesity? Current Opinion in Endocrinology &amp; Diabetes and Obesity, 19, 81-87. https://doi.org/10.1097/MED.0b013e3283514e13</mixed-citation></ref><ref id="scirp.106705-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Amato, M.C., Giordano, C., Galia, M., Criscimanna, A., Vitabile, S., Midiri, M. and Galluzzo, A. (2010) Visceral Adiposity Index: A Reliable Indicator of Visceral Fat Function Associated with Cardiometabolic Risk. Diabetes Care, 33, 920-922.https://doi.org/10.2337/dc09-1825</mixed-citation></ref><ref id="scirp.106705-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">&amp;#352;těpánek, L., Horáková, D., Cibi&amp;#269;ková, &amp;#317., Vaverková, H., Karásek, D., Nakládalová, M. and Zapletalová, J. (2019) Can Visceral Adiposity Index Serve as a Simple Tool for Identifying Individuals with Insulin Resistance in Daily Clinical Practice? Medicina, 55, 545. https://doi.org/10.3390/medicina55090545</mixed-citation></ref><ref id="scirp.106705-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lear, S.A., Humphries, K.H., Kohli, S., Chockalingam, A., Frohlich, J.J. and Birmingham, C.L. (2007) Visceral Adipose Tissue Accumulation Differs According to Ethnic Background: Results of the Multicultural Community Health Assessment Trial (M-CHAT). The American Journal of Clinical Nutrition, 86, 353-359. https://doi.org/10.1093/ajcn/86.2.353</mixed-citation></ref><ref id="scirp.106705-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Parveen, S., Ayub, T.E., Haq, T., Nahar, N., Manbub, N., Islam, F., Aktar, F. and Aziz, M. (2020) Association of Visceral Adiposity Index with Insulin Resistance in Adults with Diabetes Mellitus. IMC Journal of Medical Science, 14, 5-12. https://doi.org/10.3329/imcjms.v14i1.47382</mixed-citation></ref><ref id="scirp.106705-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2008) Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. https://apps.who.int/iris/bitstream/handle/10665/44583/9789241501491_eng.pdf?sequence=1</mixed-citation></ref><ref id="scirp.106705-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kaplan, A. and Glucose, K. (1984) ClinChem. C.V. Mosby Co., St Louis, Toronto, Princeton, 436 p.</mixed-citation></ref><ref id="scirp.106705-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2000) The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. https://apps.who.int/iris/handle/10665/206936</mixed-citation></ref><ref id="scirp.106705-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Alberti, K.G.M.M., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., Fruchart, J-C., James, W.P.T., Loria, C.M. and Smith Jr., S.C. (2009) Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120, 1640-1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644</mixed-citation></ref><ref id="scirp.106705-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, B.F. and Turner, R.C. (1985) Homeostasis Model Assessment: Insulin Resistance and β-Cell Function from Fasting Plasma Glucose and Insulin Concentrations in Man. Diabetologia, 28, 412-419. https://doi.org/10.1007/BF00280883</mixed-citation></ref><ref id="scirp.106705-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bhowmik, B., Siddiquee, T., Mujumder, A., Rajib, M.M.R., Das, C.K., Khan, M.I., Khan, A.K.A. and Hussain, A. (2016) Identifying Insulin Resistance by Fasting Blood Samples in Bangladeshi Population with Normal Blood Glucose. Journal of Diabetes, 7, 4.</mixed-citation></ref><ref id="scirp.106705-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y., Feng, Y., Ma, X., Chen, K., Wu, N., Wang, D., Li, P., Wang, M., Li, Q. and Zhang, J. (2015) Visceral Adiposity Index and Insulin Secretion and Action in First-Degree Relatives of Subjects with Type 2 Diabetes. Diabetes/Metabolism Research and Reviews, 31, 315-321. https://doi.org/10.1002/dmrr.2615</mixed-citation></ref><ref id="scirp.106705-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, S., Shi, S., Ren, X., Han, T., Li, Y., Chen. Y., Liu, W., Hou, P.C. and Yaomin, H. (2016) Triglyceride Glucose-Waist Circumference, a Novel and Effective Predictor of Diabetes in First-Degree Relatives of Type 2 Diabetes Patients: Cross-Sectional and Prospective Cohort Study. Journal of Translational Medicine, 14, Article No. 260. https://doi.org/10.1186/s12967-016-1020-8</mixed-citation></ref><ref id="scirp.106705-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Nusrianto, R., Ayundini, G., Kristanti, M., Astrella, C., Amalina, N., Muhadi, Riyadina, W., Tahapary, D.L. and Soewondo. P. (2019) Visceral Adiposity Index and Lipid Accumulation Product as a Predictor of Type 2 Diabetes Mellitus: The Bogor Cohort Study of Non-Communicable Diseases Risk Factors. Diabetes Research and Clinical Practice, 155, Article ID: 107798. https://doi.org/10.1016/j.diabres.2019.107798</mixed-citation></ref><ref id="scirp.106705-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kumpatla, S., Michael, C. and Viswanathan, V. (2011) Visceral Adiposity Index and Pattern of Dyslipidaemia at Different Stages of Glucose Intolerance—A Study from India. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews, 5, 173-178. https://doi.org/10.1016/j.dsx.2012.05.003</mixed-citation></ref><ref id="scirp.106705-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C., Xu, Y., Guo, Z.-R., Yang, J., Wu, M. and Hu, X.S. (2014) The Application of VAI in Identifying type 2 Diabetes Risks Based on a Prospective Cohort in China. Lipids in Health and Disease, 13, Article No. 108. https://doi.org/10.1186/1476-511X-13-108</mixed-citation></ref><ref id="scirp.106705-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Brahimaj, A., Rivadeneira, F., Muka, T., Sijbrands, E.J., Franco, O.H., Dehghan, A. and Kavousi, M. (2019) Novel Metabolic Indices and Incident Type 2 Diabetes among Women and Men: The Rotterdam Study. Diabetologia, 62, 1581-1590.https://doi.org/10.1007/s00125-019-4921-2</mixed-citation></ref><ref id="scirp.106705-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Fiorentino, T.V., Marini, M.A., Succurro, E., Andreozzi, F. and Sesti, G. (2019) Relationships of Surrogate Indexes of Insulin Resistance with Insulin Sensitivity Assessed by Euglycemic Hyperinsulinemic Clamp and Subclinical Vascular Damage. BMJ Open Diabetes Research &amp; Care, 7, e000911. http://dx.doi.org/10.1136/bmjdrc-2019-000911</mixed-citation></ref><ref id="scirp.106705-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Liu, P.J., Ma, F., Lou, H.P. and Chen, Y. (2016) VAI Is Associated with Pre-Diabetes and Diabetes Mellitus in Chinese Adults Aged 20-50. Annals of Nutrition and Metabolism, 68, 235-243. https://doi.org/10.1159/000446121</mixed-citation></ref><ref id="scirp.106705-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Samuel, V.T., Petersen, K.F. and Shulman, G.I. (2010) Lipid-Induced Insulin Resistance: Unravelling the Mechanism. Lancet, 375, 2267-2277. https://doi.org/10.1016/S0140-6736(10)60408-4</mixed-citation></ref><ref id="scirp.106705-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Du, T., Yuan, G., Zhang, M., Zhou, X., Sun, X. and Yu, X. (2014) Clinical Usefulness of Lipid Ratios, Visceral Adiposity Indicators, and the Triglycerides and Glucose Index as Risk Markers of Insulin Resistance. Cardiovascular Diabetology, 13, Article No. 146. https://doi.org/10.1186/s12933-014-0146-3</mixed-citation></ref><ref id="scirp.106705-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Gu, D., Ding, Y., Zhao, Y. and Qu, Q. (2018) Visceral Adiposity Index was a Useful Predictor of Prediabetes. Experimental and Clinical Endocrinology &amp; Diabetes, 126, 596-603. https://doi.org/10.1055/s-0043-120440</mixed-citation></ref><ref id="scirp.106705-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ahn, N., Baumeister, S.E., Amann, U., Rathmann, W., Peters, A., Huth, C., Thorand, B. and Meisinger, C. (2019) Visceral Adiposity Index (VAI), Lipid Accumulation Product (LAP), and Product of Triglycerides and Glucose (TyG) to Discriminate Prediabetes and Diabetes. Scientific Reports, 9, Article No. 9693. https://doi.org/10.1038/s41598-019-46187-8</mixed-citation></ref></ref-list></back></article>